###begin article-title 0
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Alterations in the highly penetrant cancer susceptibility gene BRCA1 are responsible for the majority of hereditary breast and/or ovarian cancers. However, the number of detected germline mutations has been lower than expected based upon genetic linkage data. Undetected deleterious mutations in the BRCA1 gene in some high-risk families could be due to the presence of intragenic rearrangements as deletions, duplications or insertions spanning whole exons. Standard PCR-based screening methods are mainly focused on detecting point mutations and small insertions/deletions, but large rearrangements might escape detection.
###end p 3
###begin p 4
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
The purpose of this study was to determine the type and frequency of large genomic rearrangements in the BRCA1 gene in hereditary breast and ovarian cancer cases in the Czech Republic.
###end p 4
###begin title 5
Methods
###end title 5
###begin p 6
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 266 274 266 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Multiplex ligation-dependent probe amplification (MLPA) was used to examine BRCA1 rearrangements in 172 unrelated patients with hereditary breast and/or ovarian cancer syndrome without finding deleterious mutation after complete screening of whole coding regions of BRCA1/2 genes. Positive MLPA results were confirmed and located by long-range PCR. The breakpoints of detected rearrangements were characterized by sequencing.
###end p 6
###begin title 7
Results
###end title 7
###begin p 8
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Six different large deletions in the BRCA1 gene were identified in 10 out of 172 unrelated high-risk patients: exons 1A/1B and 2 deletion; partial deletion of exon 11 and exon 12; exons 18 and 19 deletion; exon 20 deletion; exons 21 and 22 deletion; and deletion of exons 5 to 14. The breakpoint junctions were localized and further characterized. Destabilization and global unfolding of the mutated BRCT domains explain the molecular and genetic defects associated with the exon 20 in-frame deletion and the exon 21 and 22 in-frame deletion, respectively.
###end p 8
###begin title 9
Conclusion
###end title 9
###begin p 10
###xml 89 97 89 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
###xml 255 261 255 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 185 193 <span type="species:ncbi:9606">patients</span>
###xml 289 297 <span type="species:ncbi:9606">patients</span>
Using MLPA, mutations were detected in 6% of high-risk patients previously designated as BRCA1/2 mutation-negative. The breakpoints of five out of six large deletions detected in Czech patients are novel. Screening for large genomic rearrangements in the BRCA1 gene in the Czech high-risk patients is highly supported by this study.
###end p 10
###begin title 11
Background
###end title 11
###begin p 12
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 474 480 474 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 721 727 721 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 731 737 731 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 829 830 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 55 60 <span type="species:ncbi:9606">women</span>
###xml 465 468 <span type="species:ncbi:9606">Man</span>
Breast cancer is the most commonly diagnosed cancer in women in Europe today. A hereditary form of breast cancer is characterized by young age onset, increased risk of bilateral breast cancer, and its being frequently in association with ovarian cancer. The existence of an autosomal dominant pattern of inheritance accounting for 5-10% of the breast cancer cases has been demonstrated [1]. Germline mutations in BRCA1 (OMIM#113705, Online Mendelian Inheritance in Man) and BRCA2 (OMIM#600185) genes are responsible for an important fraction of hereditary breast and ovarian cancers [2]. A few hundred different mutations associated with inherited predisposition to breast and ovarian cancers have been identified in the BRCA1 and BRCA2 genes, as described at the Breast Cancer Information Core internet web site (BIC database) [3].
###end p 12
###begin p 13
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 132 134 132 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2 </italic>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 401 407 401 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 454 459 454 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 585 591 585 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 754 755 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1008 1014 1008 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1045 1046 1045 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1047 1048 1047 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1067 1069 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1096 1102 1096 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1122 1124 1122 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1125 1127 1125 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1162 1164 1162 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1165 1167 1165 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1187 1189 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1354 1360 1354 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1395 1397 1395 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Most reported germline deleterious mutations are nonsense substitutions and small deletions/insertions causing truncations of BRCA1/2 proteins. In most populations tested, the observed frequencies of BRCA1 variations in high-risk breast and/or ovarian cancer families have been described as lower than predicted by linkage analysis. Pathogenic mutations in the coding region or in splice sites of the BRCA1 gene were found in approximately two-thirds of BRCA1-linked families [2]. This finding suggests that methods generally used for mutation scanning fail to detect certain types of BRCA1 germline defects, such as large intragenic rearrangements. Most of the screening methods based on the PCR of genomic DNA are qualitative rather than quantitative [4]. Partial or complete exon loss or amplification might be overlooked because of the presence of a wild-type allele that gives rise to a positive PCR signal and therefore a possible false-negative result. Several approaches have been used for detecting BRCA1 rearrangements: Southern blot [5-9], long-range PCR [10], color bar coding of the BRCA1 gene on combed DNA [11,12], semiquantitative-multiplex PCR [13,14] or real-time PCR [15]. Recently, multiplex ligation-dependent probe amplification (MLPA) has been widely used as a highly sensitive method for detecting the relative copy number of all BRCA1 exons in a high-throughput format [16].
###end p 13
###begin p 14
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 297 303 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alu </italic>
###xml 417 423 417 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 450 456 450 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 573 579 573 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 678 679 678 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 818 820 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1125 1131 1125 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1226 1228 1226 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1353 1359 1353 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1368 1369 1368 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1398 1404 1398 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 961 969 <span type="species:ncbi:9606">patients</span>
###xml 1038 1046 <span type="species:ncbi:9606">patients</span>
Many different BRCA1 germline rearrangements with mapped breakpoints have been reported to date [17]. These are scattered throughout the whole gene and most of them are deletions, but duplication, triplication or combined deletion/insertion events also have been described. A genetic structure of BRCA1 with extremely high density of intronic Alu repeats and the presence of a duplicated promoter region containing a BRCA1 pseudogene upstream of the BRCA1 could provide hotspots for unequal homologous recombination [18,19]. The proportion of genomic rearrangements in the BRCA1 mutation spectrum has been studied in several countries and often was found to vary from 8 to 15% [7,20-23]. Higher values, probably due to a strong founder effect, have been presented by studies performed in the Netherlands and Italy [24,25]. The majority of known rearrangements create frame shifts that result in premature termination of translation. Therefore, the phenotype of patients carrying this type of mutations is not expected to be distinct from patients with other truncating mutations. Most mutations introducing a stop codon into BRCA1 have been described as leading to nonsense-mediated decay of mRNA, irrespective of their type [26]. Large deletions of one or more exons maintaining the reading frame could cause loss of putative functional domains of the BRCA1 protein [8]. However, no assay for the BRCA1 gene is currently available for testing the exact functional consequences of such mutations.
###end p 14
###begin p 15
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 168 172 168 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA</italic>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 492 498 492 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
The presence of large rearrangements in the BRCA1 gene offers a promising outlook in clinical practice, and especially for probands with previously negative results of BRCA1/2 mutation screening. If causative mutation is determined, predictive testing can be performed to identify family members who may benefit from increased surveillance, chemoprevention or prophylactic surgery to reduce the risk of developing cancer [27]. The aim of this study was to determine the frequency and type of BRCA1 intragenic rearrangements in Czech high-risk breast and/or ovarian cancer families where no deleterious mutations were previously found and to assess whether testing for such rearrangements should be included in standard mutation screening.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and criteria for testing
###end title 17
###begin p 18
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 636 642 636 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 646 652 646 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1123 1124 1123 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 895 903 <span type="species:ncbi:9606">patients</span>
###xml 984 992 <span type="species:ncbi:9606">patients</span>
The test group was comprised of 172 high-risk Czech families with hereditary breast and/or ovarian cancer syndrome referred for genetic testing to the Masaryk Memorial Cancer Institute in Brno (Table 1). All tested individuals were counseled and gave signed informed consent. The inclusion criteria were as follow: (i) unrelated index patients affected by invasive breast and/or ovarian cancer, (ii) at least three diagnoses of breast and/or ovarian cancer in the family diagnosed at any age (bilateral cancers were counted as two cases), and (iii) no deleterious mutation found during complete screening of the whole coding regions of BRCA1 and BRCA2 genes as described by Foretova et al. [28]. This group could be divided into two main parts consistent with the cancer phenotype of the probands' families: the individuals belonging to the families with at least one case of ovarian cancer (45 patients) and those individuals from the families with breast cancer phenotype only (127 patients). These were further subdivided according to the number of individuals diagnosed with breast cancer at ages under 50 years (Table 1).
###end p 18
###begin p 19
Molecular genetic testing in 290 Czech high-risk families
###end p 19
###begin p 20
###xml 28 36 <span type="species:ncbi:9606">Patients</span>
*See Materials and methods, Patients and criteria for testing. Only deleterious mutations are considered. HBOC - hereditary breast and ovarian cancer syndrome; HOC - hereditary ovarian cancer syndrome; HBC - hereditary breast cancer syndrome.
###end p 20
###begin title 21
Detecting large genomic rearrangements using MLPA
###end title 21
###begin p 22
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 582 584 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1225 1232 <span type="species:ncbi:9606">patient</span>
Relative quantification of the copy numbers of all 24 BRCA1 exons was performed by the Salsa P002 BRCA1 MLPA probe mix assay (M.R.C. Holland, Amsterdam, the Netherlands) as described by the manufacturer [29]. Each MLPA analysis was carried out on 10 samples and 2 controls on a PTC-200 thermal cycler (Bio-Rad, Hercules, CA, USA). PCR products were separated on an ALFexpresstrade mark II (Amersham Pharmacia Biotech, Uppsala, Sweden) or an ABI PRISM 310 (Applied Biosystems, Foster City, USA) instrument. A peak pattern of 34 peaks ranging in size from 127 to 454 bp was detected [16]. The data obtained on the capillary sequencer ABI-310 were analyzed using GeneScan 3.1.2 Software. The peak heights were normalized and deletions were suspected when the peak height was lower than 65% of the controls. The positive MLPA results were confirmed using new DNA samples in independent assays. DNA sequence analysis of the appropriate ligation sites was done in the case of single exon deletions to eliminate the possibility of an amplification artifact or a presence of polymorphism in ligation sites. False-positive deletions or duplications of single exons were resolved by repeated testing of independent DNA samples for the patient.
###end p 22
###begin title 23
Confirmation and characterization of the rearrangements
###end title 23
###begin p 24
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 519 520 519 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1243 1247 1234 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alu </italic>
###xml 1282 1284 1273 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Positive results detected by MLPA of two independently drawn samples of genomic DNA were confirmed by long-range PCR (Expand Long Template PCR System, Roche Applied Science), conducted in accordance with the manufacturer's instructions. Several pairs of primers located in exons or introns flanking the rearrangements were used to localize the breakpoint junctions. The GeneFisher program was used for primer design [30]. Selected primers used for long-range PCR of detected Czech rearrangements are presented in Table 2. PCR products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining. A smaller fragment corresponding to the allele with deletion compared to the wild-type allele was obtained in all six deletions detected in this study. Such aberrant DNA fragments were cut out and isolated from agarose gel (QIAquick gel extraction Kit, QIAGEN, Hilden, Germany), sequenced with appropriate primers (ThermoSequenase Cy5 Dye Terminator Cycle Sequencing Kit, Amersham Biosciences, UK), and analyzed on an ALFexpresstrade mark II sequencer (Amersham Pharmacia Biotech, Uppsala, Sweden) or an ABI 3130 genetic analyzer (Applied Biosystems, Foster City, USA). The Repeat Masker program was used to identify Alu sequences at breakpoint junctions [31].
###end p 24
###begin p 25
PCR primers used for long-range PCR
###end p 25
###begin p 26
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
aRegion of BRCA1 genomic sequence amplified by primer pair (nucleotide position, [GenBank: ]).
###end p 26
###begin p 27
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bDeleted allele.
###end p 27
###begin title 28
Nomenclature
###end title 28
###begin p 29
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 256 261 <span type="species:ncbi:9606">human</span>
Detected mutations were described at the gDNA level according to the GenBank Database BRCA1 reference sequence L78833 (or to the sequence of BAC clone AC060780 in case of the deletion of 1A/1B-2 exons) and following the recommended nomenclature system for human gene mutations [32].
###end p 29
###begin title 30
Structural interpretation of mutations
###end title 30
###begin p 31
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
The crystal structures of the BRCT domains of the BRCA1 protein [33] (PDB-ID ) and its complexes with the tumor suppressor p53 [34] (PDB-ID ), with the phosphorylated bach1 peptide [35] (PDB-ID ), with the phosphopeptides [36,37] (PDB-IDs  and ), and with the phosphorylated interacting region from bach1 helicase [38] (PDB-ID ) were inspected using the PyMol viewer v0.99 (DeLano Scientific, LLC).
###end p 31
###begin title 32
Results and discussion
###end title 32
###begin p 33
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 318 324 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 796 797 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 729 737 <span type="species:ncbi:9606">patients</span>
The MLPA analysis of genomic DNA of 172 affected individuals from high-risk families with hereditary breast and/or ovarian cancer syndrome revealed six different deletions covering 1.9-36.9 kb of the BRCA1 genomic DNA (Figure 1, Table 3). The average age at the onset of the cancer diagnosis in probands with detected BRCA1 rearrangements was 40 years. The effect of decreasing age at onset of the illness in younger generations could be observed in some families. Except for two rearrangements including the exons 5-14 and 11-12, the deletions spanning the exons 1A/1B-2, 18-19, 20 and 21-22 had been previously described in the literature [6,8,19,25,39]. However, the breakpoints of five out of six deletions detected in Czech patients were different from those characterized previously (Table 3).
###end p 33
###begin p 34
###xml 0 125 0 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Multiplex ligation-dependent probe amplification (MLPA) electropherogram (ABI PRISM 310 genetic analyzer, Applied Biosystems)</bold>
###xml 198 204 198 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 254 257 254 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink">"c"</bold>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 409 415 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Multiplex ligation-dependent probe amplification (MLPA) electropherogram (ABI PRISM 310 genetic analyzer, Applied Biosystems). Probe mix P002 contains 34 probes: nine control probes recognizing non-BRCA1 sequences on various chromosomes are indicated by "c"; exons recognized by the BRCA1-specific probes are indicated by numbers (probes for both alternative exons 1...1A, 1B; exon 4 is not present in normal BRCA1 transcript; two probes specific for exon 11 are included). Note decreased peak heights of deleted exons.
###end p 34
###begin p 35
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
BRCA1 germline rearrangements identified in the BRCA1 gene
###end p 35
###begin p 36
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aInferred from change at the DNA level.
###end p 36
###begin p 37
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 7 12 <span type="species:ncbi:9606">human</span>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
bHBC - human breast cancer, HBOC - human breast and ovarian cancer, HOC - human ovarian cancer.
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cBased on the BAC clone sequence AC060780.
###end p 38
###begin p 39
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 501 510 501 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#968;BRCA1 </italic>
###xml 529 535 527 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 633 635 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 734 743 732 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#968;BRCA1 </italic>
###xml 763 769 759 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 782 784 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 889 898 885 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#968;BRCA1 </italic>
###xml 929 935 923 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 945 947 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1010 1019 1004 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#968;BRCA1 </italic>
###xml 1051 1057 1043 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1142 1151 1134 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#968;BRCA1 </italic>
###xml 1171 1177 1161 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1297 1299 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1300 1302 1290 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
The deletion of 1A/1B-2 exons was detected by MLPA in one family with the mother affected with ovarian cancer at age 43 and with two relatives affected with breast cancer at young age: her daughter at the age of 38 and her sister at age 39. The deletion of 1A/1B-2 exons was confirmed by long-range PCR with primers published by Puget et al. [19] (Figure 2A). The intensive PCR product was created only for the mutant allele and sequencing revealed the 36.9 kb deletion extending from intron 2 of the psiBRCA1 to intron 2 of the BRCA1 gene. The breakpoint region is consistent with that reported previously by Preisler-Adams et al. [40] and comprises 188 bp of perfect nucleotide homology between sequences located in the intron 2 of psiBRCA1 and intron 2 of the BRCA1 gene (Figure 2A). Based on the BAC clone sequence AC060780, the breakpoints occurred between nucleotides 71053-71240 in psiBRCA1 and nucleotides 34118-34305 in BRCA1 intron 2 [40]. The mutant allele harbors a chimeric gene consisting of the psiBRCA1 exons 1A, 1B and 2 fused to the BRCA1 exons 3-24 as a result of recombination between sequences located in the intron 2 of psiBRCA1 and intron 2 of the BRCA1 gene. The promoter was shown to be absent from this mutant allele and expression of the mutant allele was not observed [19,25].
###end p 39
###begin p 40
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Confirmation and characterization of the rearrangements</bold>
###xml 57 61 57 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 160 164 160 164 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 260 264 260 264 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
Confirmation and characterization of the rearrangements. (A) Confirmation of the deletion of exons 1A/1B-2 by long-range PCR and sequencing of the breakpoints. (B) Confirmation of the deletion of exons 5-14 by long-range PCR and sequencing of the breakpoints. (C) Confirmation of the deletion of exons 11-12 by long-range PCR and sequencing of the breakpoints. Lanes 1+, 2+, carriers of the deletion; lane C-, negative control (wt); lane B, blank; lane M, marker (Ready-Loadtrade mark 1 Kb DNA Ladder, Invitrogen).
###end p 40
###begin p 41
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 357 363 357 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 470 476 470 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 625 631 625 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 738 739 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1183 1184 1183 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1185 1187 1185 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
Deletion of the BRCA1 exons 5 to 14 was revealed by MLPA in four high-risk, severely affected families with young-age onset of cancer: two families with the hereditary breast-ovarian cancer syndrome and two families with only the breast cancer syndrome. Long-range PCR confirmed a deletion of 31.5 kb of genomic DNA spanning more than three-quarters of the BRCA1 gene coding sequence. This deletion interferes with the RING domain (N-terminal zinc finger domain) of the BRCA1 protein as well as with important interaction domains for multiple proteins, and it is suggestive of having a negative impact on the function of the BRCA1 protein. The exact breakpoints were characterized by sequencing as g.21716_53298del31583 (Figure 2B, Table 3). The breakpoint junctions determined in all four families were identical, thus supporting the likelihood of the founder effect. Moreover, three of the four individuals with confirmed deletion of exons 5-14 came from the same geographical region of the Czech Republic. Only haplotype analysis could reveal if repeated observation of these four deletions is due to the presence of founder mutation or only to the local instability in a region [7,22].
###end p 41
###begin p 42
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 542 548 542 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 142 147 <span type="species:ncbi:9606">women</span>
The deletion of the second part of the exon 11 and exon 12 was found by MLPA in a family with ovarian cancer phenotype only. Altogether, five women in two generations were affected with ovarian cancer at ages ranging from 34 to 56 years (Figure 3). Long-range PCR confirmed a deletion of 6.5 kb of genomic DNA spanning nearly one-half of the BRCA1 gene coding sequence. The exact breakpoints were characterized by sequencing as g.34845_41405del6561 (Figure 2C, Table 3). An aberrant splicing of mRNA that might further extend a defect on the BRCA1 protein is suspected in this case. This deletion lies within a central-risk region where mutations were associated with a significantly higher ovarian/breast cancer ratio [41].
###end p 42
###begin p 43
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 0 101 0 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pedigrees of ovarian cancer family with detected deletion of <italic>BRCA1 </italic>exons 11&#8211;12 (g.34845_41405del6561)</bold>
Pedigrees of ovarian cancer family with detected deletion of BRCA1 exons 11-12 (g.34845_41405del6561). Circles - females, squares - males, partially filled symbols - affected individuals, arrow - proband. Type of cancer and age of onset are indicated below each affected individual (ov - ovarian). Mutation status: + carrier, - no carrier (wt).
###end p 43
###begin p 44
###xml 286 292 286 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 493 499 493 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 584 590 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 64 69 <span type="species:ncbi:9606">woman</span>
The deletion of the exons 18 and 19 was revealed by MLPA in one woman diagnosed with both breast and ovarian cancers at the ages of 52 and 59, respectively, and with a family history of breast cancer in her second-degree relatives. Long-range PCR confirmed a deletion of nearly 2 kb of BRCA1 genomic DNA. The exact breakpoints were characterized by sequencing as g.63651_65590del1940 (Figure 4A, Table 3). The out-of-frame deletion of exons 18-19 is predicted to result in a truncation of the BRCA1 protein at the codon 1693. As displayed previously, most truncating mutations of the BRCA1 gene lead to nonsense-mediated mRNA decay and an allelic imbalance in the expression of the mutant versus wild-type allele [26,42].
###end p 44
###begin p 45
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Confirmation and characterization of the rearrangements</bold>
###xml 57 61 57 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 158 162 158 162 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
Confirmation and characterization of the rearrangements. (A) Confirmation of the deletion of exons 18-19 by long-range PCR and sequencing of the breakpoints. (B) Confirmation of the deletion of exon 20 and sequencing of the breakpoints.Lanes 1+, 2+, carriers of the deletion; lane C-, negative control (wt); lane B, blank; lane M, marker (Ready-Loadtrade mark 1 Kb DNA Ladder, Invitrogen).
###end p 45
###begin p 46
###xml 273 279 273 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 531 537 531 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 623 629 623 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 683 689 683 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 51 56 <span type="species:ncbi:9606">woman</span>
The deletion of the exon 20 was found by MLPA in a woman affected with breast and colorectal cancers at the ages of 37 and 35, respectively. Her mother was affected with bilateral breast cancer at the ages of 39 and 46. Long-range PCR confirmed a deletion of about 7 kb of BRCA1 genomic DNA. The exact breakpoints were characterized by sequencing as g.68764_75792del7029 (Figure 4B, Table 3). The genomic deletion of exon 20 causes at least in-frame deletion of exon 20 in mRNA and results in the removing of 28 amino acids of the BRCA1 protein in position 1732-1759. This deletion affects the highly conserved area of the BRCA1 protein corresponding to the linker between two BRCT (BRCA1 C-terminal) domains, and it has been described to be involved in DNA repair and transcription activation [43].
###end p 46
###begin p 47
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 209 215 209 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 454 460 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
The next in-frame deletion of the exons 21 and 22 was detected by MLPA in two high-risk families with hereditary breast cancer phenotype only (Figure 5). Long-range PCR confirmed a deletion of about 3.5 kb of BRCA1 genomic DNA. Sequencing of the breakpoint's region revealed the deletion/insertion event characterized as g.77128_80906del3779ins236 (Figure 6, Table 3). However, the in-frame deletion of exons 21-22 removes at least 43 amino acids of the BRCA1 protein in position 1760-1802, corresponding to a part of the C-terminal BRCT domain.
###end p 47
###begin p 48
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 0 106 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pedigrees of breast cancer family with detected deletion of <italic>BRCA1 </italic>exons 21&#8211;22 (g.77128_80906del3779ins236)</bold>
Pedigrees of breast cancer family with detected deletion of BRCA1 exons 21-22 (g.77128_80906del3779ins236). Circles - females, squares - males, partially filled symbols - affected individuals, arrow - proband. Type of cancer and age of onset are indicated below each affected individual (br - breast). Mutation status: + carrier, - no carrier (wt).
###end p 48
###begin p 49
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Confirmation and characterization of the rearrangements</bold>
Confirmation and characterization of the rearrangements. Confirmation of the deletion of the exons 21-22 by long-range PCR and sequencing of the breakpoints. The deletion/insertion event was characterized as g.77128_80906del3779ins236. Lanes 1+, 2+, carriers of the deletion; lane C-, negative control (wt); lane B, blank; lane M, marker (Ready-Loadtrade mark 1 Kb DNA Ladder, Invitrogen).
###end p 49
###begin p 50
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 641 642 641 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
The loss of a part of the conservative domain of BRCA1 protein might have an effect on protein function and is suspected to be causative of cancer susceptibility. Even missense mutations located in this region (for example, P1749R and M1775R) were described to segregate with the disease and to have a destabilizing effect on the BRCT domain [44]. However, the exact changes in the function of the BRCA1 protein cannot be determined because a functional assay is lacking. Therefore, the structural model of deletions in the BRCT domain was constructed to help with the interpretation of an effect on the stability of the BRCT domain (Figure 7), which might be indirectly related to the disease risk [44].
###end p 50
###begin p 51
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A ribbons representation of the BRCT domain</bold>
A ribbons representation of the BRCT domain. The deletion of 28 amino acids encoded by the exon 20 correspond to the linker (colored red). The deletion of 43 amino acids encoded by the exons 21 and 22 correspond to the C-terminal repeat of BRCT (colored blue). See Results.
###end p 51
###begin p 52
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 454 456 454 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 672 673 672 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
Inspection of the crystal structures of the BRCT repeat region from the BRCA1 revealed that the mutant with genomic deletion of exon 20 encodes the protein with the missing linker region between the N-terminal and the C-terminal BRCT repeats of BRCA1, while the in-frame deletion of exons 21 and 22 results in the protein with the missing C-terminal repeat of BRCT (Figure 7). The two BRCT domains interact in a head-to-tail fashion, burying about 1600 A2 of solvent-accessible surface area in the interface [45]. The truncation of the linker or the exclusion of any of the two BRCT domains will result in the exposure of the interface and the protein's unfolding (Figure 7). It is obvious that the protein with a disrupted carboxyl-terminal BRCT repeat region cannot fulfill its tumor suppressor function. This structural interpretation is in accordance with the study of Williams et al. [44,46], who used a protease-based assay to assess the sensitivity of the folding of the BRCT domain to an extensive set of truncation and single amino acid substitutions derived from breast cancer screening programs. The protein can tolerate truncations of up to eight amino acids, but further deletion leads to BRCT folding defects.
###end p 52
###begin p 53
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
It would have been interesting to determine whether detected deletions segregate with disease in affected families, but no informative data are available. In families with the deletion of exons 11+12 and the deletion of exons 21+22, all affected patients tested (3 and 2) were found to be carriers of the deletion (Figs. 3 and 5). In the cases of the remaining eight families, as there were no other affected individuals alive, only healthy individuals from mainly younger generations could be tested.
###end p 53
###begin p 54
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 121 125 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alu </italic>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alu </italic>
###xml 337 340 337 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alu</italic>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Alu </italic>
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 760 766 760 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Most of the previously characterized rearrangements in the BRCA1 gene result from an unequal homologous recombination of Alu repeats [17]. The presence of Alu elements revealed by the Repeat Masker program in breakpoint junctions in three out of five novel deletions characterized in this study supports this hypothesis. Contrary to the Alu-mediated deletions of exons 18-19, 20 and 20-21, no Alu repeats were found in the breakpoints of the deletions including exons 11-12 and 5-14 (Table 3). In these two cases, L1 repetitive sequences present near one side of the breakpoint do not correlate with any recognizable repeat motifs opposite, suggesting nonhomologous events or other mechanisms [10,39]. The role of the L1 repetitive elements in relation to the BRCA1 intragenic rearrangements has not yet been mentioned.
###end p 54
###begin p 55
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 251 257 251 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 451 452 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 454 460 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1004 1010 1004 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
The intragenic deletions were detected in almost 6% of all high-risk families previously considered negative for the mutation in BRCA1 or BRCA2 genes. It represents 10.4% of all detected BRCA1 mutations and 7.8% of all mutations detected in BRCA1 and BRCA2 genes (in 290 high-risk families tested for mutations during 1999-2006, Table 1). This ratio is dependent on the selection of patients and the mutation detection rate. As can be seen from Table 1, BRCA1 rearrangements were found either in breast plus ovarian cancer families (5 cases) or in breast cancer families with at least one individual with breast cancer diagnosed under 50 years of age (5 cases). The deletions were identified in all three families, each with four individuals affected by breast cancer under age 50. By contrast, no rearrangement was detected in families with late-onset multiple breast cancer cases. In affected families, ovarian cancer or at least one case of breast cancer under age 50 seems to suggest the presence of BRCA1 gross rearrangement.
###end p 55
###begin p 56
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 159 167 159 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
###xml 653 659 653 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 680 685 680 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
The proportion of intragenic BRCA1 rearrangements could be overestimated because of a higher objective amount of pathogenic mutations in the Czech population. BRCA1/2 mutations were excluded in this study using a combination of heteroduplex analysis and protein truncation tests. Heteroduplex analysis is aimed to detect small insertions and deletions and not at detecting single base changes. The protein truncation test is a convenient method for rapidly scanning relatively large fragments for protein-terminating variants, but it is incapable of identifying some potentially risky missense variants or small in-frame deletions located in exon 11 of BRCA1 or exon 10 and 11 of BRCA2.
###end p 56
###begin p 57
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 349 355 349 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 462 468 462 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 631 637 631 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1083 1089 1083 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Our results are in good concordance with those obtained by studies performed in other countries: the proportion of the BRCA1 intragenic rearrangements is slightly higher than are those estimated in France, Germany, Spain and in the United States [7,20,21,23] but lower than in the populations of Australia or New Zealand [22]. Higher proportions of BRCA1 rearrangements have been observed in the Netherlands, due to the founder mutations representing 23% of all BRCA1 mutations found [24], and in a small population in Northern Italy [25]. On the other hand, a study performed in Finland failed to detect any rearrangements in the BRCA1 gene [47]. The most likely explanation for varying prevalencies of large rearrangements is in the differing genetic backgrounds of the populations studied. The study size and selection bias may be relevant, too. Methodology is not supposed to be a major factor, because the same commercially available MLPA kit is widely used. Our results indicate that MLPA is a rapid, reliable and sensitive technique allowing high-throughput screening for the BRCA1 rearrangements.
###end p 57
###begin title 58
Conclusion
###end title 58
###begin p 59
###xml 139 147 139 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 312 318 312 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 533 539 533 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
Using MLPA technique, intragenic rearrangements were detected in approximately 6% of the Czech high-risk families previously designated as BRCA1/2 mutation negative. Six different intragenic deletions represent more than 10% of all detected BRCA1 mutations. Our results prove the usefulness of testing for large BRCA1 rearrangements in the Czech population. These results are important for counseling purposes and clinical management of patients as well as for the possibility of predictive testing of relatives. MLPA testing of the BRCA2 rearrangements is now under examination and might further improve the sensitivity of testing.
###end p 59
###begin title 60
Competing interests
###end title 60
###begin p 61
The author(s) declare that they have no competing interests.
###end p 61
###begin title 62
Authors' contributions
###end title 62
###begin p 63
PV and EM contributed equally to this work.
###end p 63
###begin p 64
PV, EM and LF participated in design of this study.
###end p 64
###begin p 65
###xml 23 31 <span type="species:ncbi:9606">patients</span>
PV, EM and ML selected patients and their family members appropriate for this study, carried out molecular analyses and interpreted the results.
###end p 65
###begin p 66
###xml 62 70 <span type="species:ncbi:9606">patients</span>
LF and MN participated in genetic counseling and selection of patients.
###end p 66
###begin p 67
PV drafted the paper and finalized the manuscript with help of EM and LF.
###end p 67
###begin p 68
OH carried out capillary electrophoresis on an ABI PRISM 310 genetic analyzer.
###end p 68
###begin p 69
JD performed structural analysis of BRCT domain and its interpretation.
###end p 69
###begin p 70
HP, VK and JK participated in mutation screening.
###end p 70
###begin p 71
All authors read and approved the final manuscript.
###end p 71
###begin title 72
Pre-publication history
###end title 72
###begin p 73
The pre-publication history for this paper can be accessed here:
###end p 73
###begin p 74

###end p 74
###begin title 75
Acknowledgements
###end title 75
###begin p 76
###xml 96 104 <span type="species:ncbi:9606">patients</span>
The authors would like to thank to all the medical geneticist and clinicians for recruiting the patients and collecting clinical data.
###end p 76
###begin p 77
This project was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic, Grant No. NR/8213-3; and the Ministry of Education, Grant No. LC06010.
###end p 77
###begin article-title 78
###xml 15 20 <span type="species:ncbi:9606">human</span>
Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families
###end article-title 78
###begin article-title 79
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Genetic heterogeneity and penetrance of the BRCA1 and BRCA2 genes in breast cancer families
###end article-title 79
###begin article-title 80
Breast Cancer Information Core internet web site
###end article-title 80
###begin article-title 81
The detection of large deletions or duplications in genomic DNA
###end article-title 81
###begin article-title 82
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
###end article-title 82
###begin article-title 83
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family
###end article-title 83
###begin article-title 84
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions
###end article-title 84
###begin article-title 85
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
In-frame deletions of BRCA1 may define critical functional domains
###end article-title 85
###begin article-title 86
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing
###end article-title 86
###begin article-title 87
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Complex germline rearrangements of BRCA1 associated with breast and ovarian cancer
###end article-title 87
###begin article-title 88
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Color bar coding the BRCA1 gene on combed DNA: a useful strategy for detecting large gene rearrangements
###end article-title 88
###begin article-title 89
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 75 81 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families
###end article-title 89
###begin article-title 90
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments
###end article-title 90
###begin article-title 91
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Screening for large rearrangements of the BRCA1 gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method
###end article-title 91
###begin article-title 92
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families
###end article-title 92
###begin article-title 93
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification
###end article-title 93
###begin article-title 94
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Genomic rearrangements in the BRCA1 and BRCA2 genes
###end article-title 94
###begin article-title 95
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 52 57 <span type="species:ncbi:9606">human</span>
Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1
###end article-title 95
###begin article-title 96
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot
###end article-title 96
###begin article-title 97
Significant contribution of large genomic rearrangements in 120 French breast cancer families
###end article-title 97
###begin article-title 98
###xml 6 12 6 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families
###end article-title 98
###begin article-title 99
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families
###end article-title 99
###begin article-title 100
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer
###end article-title 100
###begin article-title 101
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative Method
###end article-title 101
###begin article-title 102
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families
###end article-title 102
###begin article-title 103
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons
###end article-title 103
###begin article-title 104
Breast and ovarian cancer
###end article-title 104
###begin article-title 105
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 29 34 <span type="species:ncbi:9606">women</span>
BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic
###end article-title 105
###begin article-title 106
MRC-Holland
###end article-title 106
###begin article-title 107
GeneFisher - Interactive PCR Primer Design
###end article-title 107
###begin article-title 108
RepeatMasker Web Server
###end article-title 108
###begin article-title 109
###xml 46 51 <span type="species:ncbi:9606">human</span>
Recommendations for a nomenclature system for human gene mutations
###end article-title 109
###begin article-title 110
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1
###end article-title 110
###begin article-title 111
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the BRCA1 BRCT structure
###end article-title 111
###begin article-title 112
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling
###end article-title 112
###begin article-title 113
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1
###end article-title 113
###begin article-title 114
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Structural basis for cell cycle checkpoint control by the BRCA1 -CtIP complex
###end article-title 114
###begin article-title 115
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer
###end article-title 115
###begin article-title 116
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer
###end article-title 116
###begin article-title 117
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin
###end article-title 117
###begin article-title 118
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Variation in BRCA1 cancer risks by mutation position
###end article-title 118
###begin article-title 119
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Identification of BRCA1 and BRCA2 by carriers by allele-specific gene expression (AGE) analysis
###end article-title 119
###begin article-title 120
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Roles of BRCA1 and its interacting proteins
###end article-title 120
###begin article-title 121
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Detection of protein folding defects caused by BRCA1 -BRCT truncation and missense mutations
###end article-title 121
###begin article-title 122
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1
###end article-title 122
###begin article-title 123
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Structural consequences of a cancer-causing BRCA1 -BRCT missense mutation
###end article-title 123
###begin article-title 124
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Exclusion of large deletions and other rearrangementsin BRCA1 and BRCA2 in Finnish breast and ovarian cancer families
###end article-title 124

